05B4 Werner-Wasik, Maria - Thomas Jefferson University - Thomas Jefferson University
mxw135

Maria Werner-Wasik, MD, FASTRO

Contact Dr. Werner-Wasik

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. A randomized trial of bevacizumab for newly diagnosed glioblastoma
  2. Vorinostat as a radiosensitizer for brain metastasis: A phase i clinical trial
  3. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance
  4. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324
  5. A pilot study of hypofractionated stereotactic radiation therapy and sunitinib in previously irr 05B4 adiated patients with recurrent high-grade glioma
  6. Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
  7. Secondary analysis of RTOG 9508, a Phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; Poststratified by the graded prognostic assessment (GPA)
  8. Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma.
  9. Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab
  10. Reduced-dose fractionated stereotactic radiotherapy for acoustic neuromas: Maintenance of tumor control with improved hearing preservation
  11. Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: Pooled secondary analysis of radiation therapy oncology group randomized trials 0212 and 0214
  12. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
  13. Impact of a radiation oncology elective on the careers of young physicians: Update on a prospective cohort study
  14. ALK inhibitor PF02341066 (Crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK
  15. Radiosurgery for the treatment of dominant hemisphere periventricular heterotopia and intractable epilepsy in a series of three patients
  16. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation therapy oncology group 0320
  17. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer
  18. Predictors of radiation oncology resident research productivity
  19. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
  20. Intensity-modulated radiation therapy and volumetric-modulated arc therapy for adult craniospinal irradiation-A comparison with traditional techniques
0